| Chapter 14: HPV vaccine introduction in industrialized countries. | |
| | |
MedLine Citation:
|
PMID: 16949999 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Introduction of a vaccine requires the achievement of three initial milestones. These are licensure by a national control authority that determines the vaccine is safe and effective, development of recommendations for use by expert advisory bodies on immunization, and obtaining funding for vaccination. Once these milestones have been achieved, a successful vaccination program requires that a number of interlinked programmatic components be brought together in a coordinated fashion. These include vaccine purchase and supply, vaccination service delivery, high coverage rates, surveillance of the vaccination program, immunization finance policies and practices, and political will. Human papillomavirus (HPV) vaccination provides unique challenges in all of these areas because of the many gaps in our knowledge. |
| | |
Authors:
|
Thomas C Wright; Pierre Van Damme; Heinz-Josef Schmitt; André Meheus |
Related Documents
:
|
21617399 - Leveraging community concerns regarding meningococcal disease to address racial and soc... 20232189 - Risk messages about hpv, cervical cancer, and the hpv vaccine gardasil in north america... 8595139 - Engineering liposomes for drug delivery: progress and problems. 2565829 - Effect of immunopotentialization on rate of vaginal smear normalization according to ap... 17628649 - Predictors of hpv vaccine acceptability: a theory-informed, systematic review. 16109349 - Parental acceptance of the human papillomavirus vaccine. 1115189 - Late seroconversion following hpv-77, de5 rubella virus vaccine. 5294589 - An outbreak of post-vaccinal rabies (rage de laboratoire) in fortaleza, brazil, in 1960... 19868739 - Experimental studies of the nasopharyngeal secretions from influenza patients : xii. th... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Vaccine Volume: 24 Suppl 3 ISSN: 0264-410X ISO Abbreviation: Vaccine Publication Date: 2006 Aug |
Date Detail:
|
Created Date: 2006-09-04 Completed Date: 2008-09-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8406899 Medline TA: Vaccine Country: Netherlands |
Other Details:
|
Languages: eng Pagination: S3/122-31 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Columbia University, 630 W. 168th Street, New York, NY 10032, USA. tcw1@columbia.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Developed Countries Female Health Services Administration* Humans Papillomavirus Infections / prevention & control* Papillomavirus Vaccines / economics, standards*, supply & distribution* |
| Chemical | |
Reg. No./Substance:
|
0/Papillomavirus Vaccines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chapter 13: Current findings from prophylactic HPV vaccine trials.
Next Document: Chapter 15: HPV vaccine use in the developing world.